Study identifies mechanism of resistance and presents a much-needed target for advanced leukemias

By | August 16, 2021
Too many “exhausted” T cells left in the wake of aggressive chemotherapy regimens for patients with advanced chronic lymphocytic leukemia (CLL) make it more challenging for chimeric antigen receptor (CAR) T cell therapy to do its job.